Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive...

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR)-engineered T cells have achieved success in treating B-cell malignancies.
• However, their efficacy against solid tumors is limited due to the immunosuppressive tumor microenvironment.
• Transforming growth factor-beta (TGF-β) is a major mediator of this immunosuppression, inhibiting T-cell function and promoting regulatory T-cell (Treg) differentiation.

Purpose of the Study:

• To review recent advances in overcoming TGF-β-mediated immunosuppression in CAR T-cell therapy for solid tumors.
• To discuss strategies for enhancing CAR T-cell potency in solid cancer treatment.
• To explore future directions for improving adoptive cell therapy efficacy.

Main Methods:

• Review of pre-clinical studies and clinical trials targeting TGF-β in adoptive cell therapy.
• Analysis of mechanisms by which TGF-β represses CAR T-cell activity.
• Discussion of novel strategies to counteract TGF-β's immunosuppressive effects.

Main Results:

• While shielding CAR T cells from TGF-β has shown utility, further strategies are needed.
• Targeting TGF-β is a promising approach to boost anti-tumor immunity in solid cancers.
• Understanding TGF-β's role is crucial for developing more effective CAR T-cell therapies.

Conclusions:

• CAR T-cell therapy requires strategies to overcome the immunosuppressive tumor microenvironment for solid tumor treatment.
• Counteracting TGF-β offers a viable path to enhance CAR T-cell efficacy against solid cancers.
• Continued research into novel therapeutic approaches is essential for advancing CAR T-cell therapy in oncology.